Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

70.0%

7 terminated/withdrawn out of 10 trials

Success Rate

30.0%

-56.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

7 terminated

Enrollment Performance

Analytics

Phase 2

7(70.0%)

Phase 1

3(30.0%)

10Total

Phase 2(7)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT00955084Phase 1Completed

Maintenance Study on the Long Term Safety of XL999

Role: lead

NCT00312780Phase 2Completed

Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

Role: lead

NCT00304590Phase 2Terminated

Study of XL999 in Patients With Multiple Myeloma

Role: lead

NCT00277303Phase 2Terminated

Study of XL999 in Patients With Metastatic Colorectal Cancer

Role: lead

NCT00277290Phase 2Terminated

Study of XL999 in Patients With Previously Treated Ovarian Cancer

Role: lead

NCT00322673Phase 2Terminated

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

Role: lead

NCT00277329Phase 2Terminated

Study of XL999 in Patients With Non-small Cell Lung Cancer

Role: lead

NCT00277316Phase 2Terminated

Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

Role: lead

NCT00104117Phase 1Completed

Study of XL999 in Adults With Solid Tumors

Role: lead

NCT00491699Phase 1Terminated

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Role: lead

All 10 trials loaded